Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Picks Ireland For Biologics

May 12, 2008 | A version of this story appeared in Volume 86, Issue 19

Pfizer will spend about $300 million in a biologics manufacturing facility in Cork, Ireland, to be located adjacent to its existing site in Ringaskiddy. The new plant, expected to be up and running by the end of 2009, will focus on process development and the production of small-scale quantities of drug candidates entering Phase II and III clinical trials. Roughly 100 new jobs will be created as a result of the investment. Pfizer says the plant ties into its broader goal of becoming one of the top five global biotherapeutics companies by 2016.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.